GlassScriptPhysician profile
Hassan Issa
NPI 1720278708
$4,507.95
in general payments reported to CMS, 2019-2025
40 companies · $515 in 2025
The $515 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,033 · 2020: $54.63 · 2022: $470 · 2023: $782 · 2024: $654 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,899 · Education: $52.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,899.05 |
| Education | $52.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $1,632.00 | 2019 | |
| Janssen Biotech, INC. | $391.11 | 2019-2024 | Erleada, Balversa, Akeega |
| Regeneron Healthcare Solutions, INC. | $290.19 | 2022-2024 | Libtayo |
| Novartis Pharmaceuticals Corporation | $242.02 | 2019-2025 | |
| Amgen INC. | $188.40 | 2019-2023 | Lumakras, Kyprolis, Xgeva |
| Astrazeneca Pharmaceuticals LP | $139.55 | 2022-2025 | Enhertu |
| Incyte Corporation | $130.69 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $124.90 | 2019-2025 | Opdivo |
| Genzyme Corporation | $122.10 | 2022-2025 | |
| Daiichi Sankyo INC. | $119.46 | 2020-2025 | Enhertu |
| Pfizer INC. | $100.72 | 2019-2025 | |
| Stemline Therapeutics INC. | $93.22 | 2023-2025 | Orserdu |
| Janssen Pharmaceuticals, INC | $85.87 | 2019-2025 | Invega Sustenna |
| Pharmacyclics LLC, An Abbvie Company | $84.86 | 2019-2023 | Imbruvica |
| Tempus Ai, INC | $77.19 | 2024-2025 | Xt Cdx |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hassan Issa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.